Plasma VEGF concentration can predict the tumor angiogenic capacity in non-small cell lung cancer

Oncol Rep. Sep-Oct 2001;8(5):1097-102. doi: 10.3892/or.8.5.1097.


We assessed the clinical utility of circulating angiogenic factors as a predictor for tumor angiogenesis in primary lung cancer. Circulating vascular endothelial growth factor (VEGF) and intratumoral VEGF were assessed by enzyme-linked immuno-sorbent assay (ELISA). There was a significant increase in the mean value of both plasma and serum VEGF concentration in primary lung cancer patients (n=97) compared to those of healthy controls (n=59). There was a significant correlation between plasma VEGF levels and microvessel density (MVD), and also between plasma VEGF and intratumoral VEGF levels. Plasma VEGF in patients with lung cancer appears to be a useful indicator of tumor angiogenesis.

MeSH terms

  • Adult
  • Aged
  • Biomarkers, Tumor / blood*
  • Blotting, Western
  • Carcinoma, Non-Small-Cell Lung / blood supply*
  • Cytokines / analysis
  • Endothelial Growth Factors / blood*
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Fibroblast Growth Factor 2 / blood
  • Humans
  • Lung Neoplasms / blood supply*
  • Lymphokines / blood*
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Neovascularization, Pathologic / blood*
  • Predictive Value of Tests
  • Sensitivity and Specificity
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors


  • Biomarkers, Tumor
  • Cytokines
  • Endothelial Growth Factors
  • Lymphokines
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors
  • Fibroblast Growth Factor 2